Notably, the association of SOCS1 mutations (the “ST2 subgroup”) with a favorable outcome was reported in all large-scale genetic studies of DLBCL (five-year OS 84% in the NCI study, 75% in the Harvard study, and 80% in the HMRN study, respectively), which corroborates the findings of our study [50]. The gene discussed is SOCS1; the disease is diffuse large B-cell lymphoma.